started · updated
Sildenafil may help limit cancer metastasis, researchers find
Researchers at the Weizmann Institute of Science have identified a potential mechanism by which sildenafil, the active ingredient in Viagra, may inhibit cancer metastasis. The study, published in the journal Cancer Research, suggests that sildenafil disrupts cholesterol trafficking within cancer cells, thereby limiting their ability to move and spread to other organs.
In laboratory tests involving mouse models and human cancer-cell cultures—specifically focusing on lung cancer, melanoma, and triple-negative breast cancer—the drug was found to interfere with the NPC1 protein. This interference causes cholesterol to accumulate in lysosomes, creating a shortage that impairs cellular energy and movement.
Observational data analyzed from 20 years of health records involving approximately 5 million Clalit members showed higher survival rates among patients who had used sildenafil. The data also indicated an additive effect when sildenafil was used in conjunction with statins, which reduce cholesterol production, whereas sildenafil disrupts internal transport.
While the findings are promising, researchers emphasize that this does not establish sildenafil as a formal cancer treatment. The evidence relies on animal models, cell cultures, and observational data, necessitating further clinical trials to determine appropriate human dosages and safety.